These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 37207534)

  • 21. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.
    Martell RE; Sermer D; Getz K; Kaitin KI
    Oncologist; 2013; 18(1):104-11. PubMed ID: 23263289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications.
    Cristina Mendonça Nogueira T; Vinicius Nora de Souza M
    Bioorg Med Chem; 2021 Sep; 46():116340. PubMed ID: 34416511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. THPdb2: compilation of FDA approved therapeutic peptides and proteins.
    Jain S; Gupta S; Patiyal S; Raghava GPS
    Drug Discov Today; 2024 Jul; 29(7):104047. PubMed ID: 38830503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration.
    Sun Z; Zhao N; Zhao X; Wang Z; Liu Z; Cui Y
    Eur J Pharm Sci; 2024 Sep; 200():106838. PubMed ID: 38960205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration : A Cross-Sectional Analysis.
    Awan FA; Becker AB; Wang Y; Kimmelman J
    Ann Intern Med; 2022 Dec; 175(12):1675-1684. PubMed ID: 36410007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Drugs Approved in 2021.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2022 Jul; 135(7):836-839. PubMed ID: 35235820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020.
    Kayki-Mutlu G; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2021 May; 394(5):839-852. PubMed ID: 33864098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013-2023).
    Marshall CM; Federice JG; Bell CN; Cox PB; Njardarson JT
    J Med Chem; 2024 Jul; 67(14):11622-11655. PubMed ID: 38995264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs.
    Brown DG
    J Med Chem; 2024 Feb; 67(3):1690-1700. PubMed ID: 38233132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in pharmaceutical targeting of clinical indications: 1930-2013.
    Kinch MS; Merkel J; Umlauf S
    Drug Discov Today; 2014 Nov; 19(11):1682-1685. PubMed ID: 24881779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
    Kesselheim AS; Wang B; Franklin JM; Darrow JJ
    BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.